EA037915B1 - Клинические композиции - Google Patents

Клинические композиции Download PDF

Info

Publication number
EA037915B1
EA037915B1 EA201890516A EA201890516A EA037915B1 EA 037915 B1 EA037915 B1 EA 037915B1 EA 201890516 A EA201890516 A EA 201890516A EA 201890516 A EA201890516 A EA 201890516A EA 037915 B1 EA037915 B1 EA 037915B1
Authority
EA
Eurasian Patent Office
Prior art keywords
cells
solution
cell
composition
subject
Prior art date
Application number
EA201890516A
Other languages
English (en)
Russian (ru)
Other versions
EA201890516A1 (ru
Inventor
Роджер Гэй
Ромма Е. Саутвик
Джадсон Ратлифф
Original Assignee
Астеллас Инститьют Фор Ридженерэйтив Медсин
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астеллас Инститьют Фор Ридженерэйтив Медсин filed Critical Астеллас Инститьют Фор Ридженерэйтив Медсин
Publication of EA201890516A1 publication Critical patent/EA201890516A1/ru
Publication of EA037915B1 publication Critical patent/EA037915B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Reproductive Health (AREA)
  • Dentistry (AREA)
EA201890516A 2015-08-18 2016-08-18 Клинические композиции EA037915B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562206821P 2015-08-18 2015-08-18
PCT/US2016/047545 WO2017031312A1 (en) 2015-08-18 2016-08-18 Clinical formulations

Publications (2)

Publication Number Publication Date
EA201890516A1 EA201890516A1 (ru) 2018-09-28
EA037915B1 true EA037915B1 (ru) 2021-06-07

Family

ID=56843032

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201890516A EA037915B1 (ru) 2015-08-18 2016-08-18 Клинические композиции
EA202190722A EA202190722A1 (ru) 2015-08-18 2016-08-18 Клинические композиции

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202190722A EA202190722A1 (ru) 2015-08-18 2016-08-18 Клинические композиции

Country Status (15)

Country Link
US (3) US11013808B2 (cg-RX-API-DMAC7.html)
EP (1) EP3334415A1 (cg-RX-API-DMAC7.html)
JP (3) JP7043392B2 (cg-RX-API-DMAC7.html)
KR (3) KR102411018B1 (cg-RX-API-DMAC7.html)
CN (2) CN108697641A (cg-RX-API-DMAC7.html)
AU (2) AU2016308818B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018003031B1 (cg-RX-API-DMAC7.html)
EA (2) EA037915B1 (cg-RX-API-DMAC7.html)
HK (1) HK1256839A1 (cg-RX-API-DMAC7.html)
IL (3) IL299326A (cg-RX-API-DMAC7.html)
MX (2) MX2018002038A (cg-RX-API-DMAC7.html)
PH (1) PH12018500371B1 (cg-RX-API-DMAC7.html)
SG (1) SG10201913250SA (cg-RX-API-DMAC7.html)
TW (3) TW202417023A (cg-RX-API-DMAC7.html)
WO (1) WO2017031312A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9993427B2 (en) * 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
IL273405B2 (en) 2014-12-30 2024-01-01 Cell Cure Neurosciences Ltd Rpe cell populations and methods of generating same
IL303401A (en) 2015-03-23 2023-08-01 Astellas Inst For Regenerative Medicine Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
SG10201913250SA (en) * 2015-08-18 2020-03-30 Astellas Inst For Regenerative Medicine Clinical formulations
EP3479832B1 (en) * 2016-06-30 2025-08-13 Healios K.K. Transplantation medium
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CN111741735A (zh) * 2017-12-29 2020-10-02 细胞治疗神经科学有限公司 视网膜色素上皮细胞组合物
EP4022042A1 (en) 2019-08-28 2022-07-06 Astellas Institute for Regenerative Medicine Methods of treating vascular diseases
WO2021041591A1 (en) 2019-08-28 2021-03-04 Astellas Institute For Regenerative Medicine Compositions and methods of treating vascular diseases
IL292610A (en) 2019-10-30 2022-07-01 Astellas Inst For Regenerative Medicine Methods for producing retinal pigment epithelium cells
JP7018527B1 (ja) 2020-12-16 2022-02-10 アニコム先進医療研究所株式会社 細胞の保存方法および細胞懸濁液
CA3225810A1 (en) * 2021-07-15 2023-01-19 Joseph Piccirilli Preservative composition for nucleic acids and biological samples and methods of use
CA3254454A1 (en) * 2022-03-16 2025-03-04 Racthera Co., Ltd. METHOD OF TRANSPLANTATION
US20250257321A1 (en) 2022-07-18 2025-08-14 Astellas Institute For Regenerative Medicine Methods of treating brain injury
CN119923464A (zh) 2022-08-23 2025-05-02 安斯泰来再生医药协会 光感受器挽救细胞（prc）组合物和治疗眼部病症的方法
EP4659755A1 (en) * 2023-02-14 2025-12-10 RACTHERA Co., Ltd. Therapeutic drug for retinal pigment epithelium tears
WO2025122978A1 (en) * 2023-12-06 2025-06-12 Bluerock Therapeutics Lp Cell cryopreservation and delivery vehicle and methods of using the same
FR3158635A1 (fr) * 2024-01-26 2025-08-01 Treefrog Therapeutics Composition biocompatible particulière comprenant des éléments cellulaires hétérogènes utile pour l’administration de thérapies cellulaires
WO2025158058A1 (fr) * 2024-01-26 2025-07-31 Treefrog Therapeutics Composition biocompatible comprenant des elements cellulaires heterogenes
FR3158633A1 (fr) * 2024-01-26 2025-08-01 Treefrog Therapeutics Composition biocompatible comprenant des éléments cellulaires hétérogènes
WO2025204688A1 (ja) * 2024-03-26 2025-10-02 株式会社ダイセル リン脂質膜保護用液体組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0562188A1 (en) * 1992-03-27 1993-09-29 Chung-Ho Chen Composition for tissues to sustain viability and biological functions in surgery and storage
EP0781547A1 (en) * 1995-12-22 1997-07-02 Chemedica S.A. Sodium hyaluronate based ophthalmic formulation for use in eye surgery
WO2014095953A1 (en) * 2012-12-18 2014-06-26 Gambro Lundia Ab Dialysis composition

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654266A (en) 1992-02-10 1997-08-05 Chen; Chung-Ho Composition for tissues to sustain viability and biological functions in surgery and storage
CN1102851C (zh) 1993-06-04 2003-03-12 生物时间公司 类血浆溶液
US6399110B1 (en) 1997-08-22 2002-06-04 Shimizu Pharmaceutical Co., Ltd. Glucose-containing preparation
GB2336109A (en) 1998-04-07 1999-10-13 Univ Bristol Ophthalmic Irrigating Solution
ES2253201T3 (es) 2000-01-11 2006-06-01 Ophtecs Corporation Preparaciones de liquido de perfusion para operaciones oftalmicas.
US7084157B2 (en) * 2002-05-17 2006-08-01 Rajeev Raut Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation
US20190282622A1 (en) 2004-01-23 2019-09-19 Astellas Institute For Regenerative Medicine Modalities for the treatment of degenerative diseases of the retina
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
SG10201912182UA (en) 2004-01-23 2020-02-27 Astellas Inst For Regenerative Medicine Improved modalities for the treatment of degenerative diseases of the retina
EP2013331A2 (en) 2006-04-14 2009-01-14 Advanced Cell Technology, Inc. Hemangio-colony forming cells
EP2054506A1 (en) * 2006-08-15 2009-05-06 Agency for Science, Technology and Research Mesenchymal stem cell conditioned medium
CA3177952A1 (en) * 2007-10-12 2009-04-23 Astellas Institute For Regenerative Medicine Improved methods of producing rpe cells and compositions of rpe cells
KR20210003301A (ko) 2008-05-06 2021-01-11 아스텔라스 인스티튜트 포 리제너러티브 메디슨 다능성 줄기세포로부터 유도된 탈핵 적혈구계 세포를 생산하는 방법
CN104774809A (zh) 2008-05-06 2015-07-15 先进细胞技术公司 血管瘤集落形成细胞和非移植血管瘤细胞
WO2011063005A2 (en) 2009-11-17 2011-05-26 Advanced Cell Technology, Inc. Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
WO2011069127A1 (en) 2009-12-04 2011-06-09 Stem Cell & Regenerative Medicine International, Inc. Large scale generation of functional megakaryocytes and platelets from human embryonic stem cells under stromal-free conditions
AU2010326027A1 (en) 2009-12-04 2012-06-21 Stem Cell & Regenerative Medicine International, Inc. Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts
EP4524568A3 (en) 2010-07-23 2025-06-18 Astellas Institute for Regenerative Medicine Methods for detection of rare subpopulations of cells and highly purified compositions of cells
HUE044778T2 (hu) 2011-11-14 2019-11-28 Astellas Inst For Regenerative Medicine Humán RPE sejt gyógyászati készítmények és alkalmazásaik
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
CN104136034B (zh) 2011-11-30 2018-04-24 安斯泰来再生医药协会 间充质基质细胞及其相关用途
WO2013086236A2 (en) 2011-12-06 2013-06-13 Advanced Cell Technology, Inc. Method of directed differentiation producing corneal endothelial cells, compositions thereof, and uses thereof
CN103783031B (zh) 2012-10-29 2015-11-18 四川新生命干细胞科技股份有限公司 一种细胞保存液
WO2014100779A1 (en) 2012-12-21 2014-06-26 Advanced Cell Technology, Inc. Methods ofr production of platelets from pluripotent stem cells and compositions thereof
US20160175362A1 (en) 2014-03-14 2016-06-23 Ocata Therapeutics, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US20160175361A1 (en) 2014-03-14 2016-06-23 Advanced Cell Technology, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
EP4292600A3 (en) 2013-03-15 2024-04-10 Astellas Institute for Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US20170274019A1 (en) 2014-09-05 2017-09-28 Astellas Institute For Regenerative Medicine Retinal ganglion cells and progenitors thereof
IL303401A (en) 2015-03-23 2023-08-01 Astellas Inst For Regenerative Medicine Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
SG10201913250SA (en) 2015-08-18 2020-03-30 Astellas Inst For Regenerative Medicine Clinical formulations
WO2021041591A1 (en) 2019-08-28 2021-03-04 Astellas Institute For Regenerative Medicine Compositions and methods of treating vascular diseases
EP4022042A1 (en) 2019-08-28 2022-07-06 Astellas Institute for Regenerative Medicine Methods of treating vascular diseases
IL292610A (en) 2019-10-30 2022-07-01 Astellas Inst For Regenerative Medicine Methods for producing retinal pigment epithelium cells
AU2022270611A1 (en) 2021-05-03 2023-10-12 Astellas Institute For Regenerative Medicine Methods of generating mature corneal endothelial cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0562188A1 (en) * 1992-03-27 1993-09-29 Chung-Ho Chen Composition for tissues to sustain viability and biological functions in surgery and storage
EP0781547A1 (en) * 1995-12-22 1997-07-02 Chemedica S.A. Sodium hyaluronate based ophthalmic formulation for use in eye surgery
WO2014095953A1 (en) * 2012-12-18 2014-06-26 Gambro Lundia Ab Dialysis composition

Also Published As

Publication number Publication date
CN119112939A (zh) 2024-12-13
KR20180048722A (ko) 2018-05-10
TW202417023A (zh) 2024-05-01
BR112018003031A2 (pt) 2018-09-18
US11957754B2 (en) 2024-04-16
MX2022010363A (es) 2022-09-21
JP7043392B2 (ja) 2022-03-29
TWI772270B (zh) 2022-08-01
IL257551B (en) 2022-04-01
BR112018003031B1 (pt) 2023-12-26
TW202245816A (zh) 2022-12-01
PH12018500371B1 (en) 2023-01-20
JP2024074803A (ja) 2024-05-31
US20210275673A1 (en) 2021-09-09
IL291163A (en) 2022-05-01
TW201717912A (zh) 2017-06-01
US20190030168A1 (en) 2019-01-31
TWI833293B (zh) 2024-02-21
IL291163B1 (en) 2023-01-01
US12419958B2 (en) 2025-09-23
KR20220090583A (ko) 2022-06-29
AU2022206757B2 (en) 2024-09-05
NZ740608A (en) 2023-09-29
EA202190722A1 (ru) 2021-10-29
CN108697641A (zh) 2018-10-23
EA201890516A1 (ru) 2018-09-28
US20190358330A9 (en) 2019-11-28
US11013808B2 (en) 2021-05-25
WO2017031312A1 (en) 2017-02-23
AU2022206757A1 (en) 2022-08-18
IL291163B2 (en) 2023-05-01
JP2022040140A (ja) 2022-03-10
KR102651291B1 (ko) 2024-03-26
JP7449915B2 (ja) 2024-03-14
KR20230058544A (ko) 2023-05-03
US20240350639A1 (en) 2024-10-24
IL257551A (en) 2018-04-30
CA2995977A1 (en) 2017-02-23
IL299326A (en) 2023-02-01
MX2018002038A (es) 2018-07-06
JP2018523682A (ja) 2018-08-23
HK1256839A1 (zh) 2019-10-04
AU2016308818A1 (en) 2018-04-05
SG10201913250SA (en) 2020-03-30
EP3334415A1 (en) 2018-06-20
KR102411018B1 (ko) 2022-06-20
AU2016308818B2 (en) 2022-04-21
PH12018500371A1 (en) 2018-08-29

Similar Documents

Publication Publication Date Title
AU2022206757B2 (en) Clinical formulations
JP7081016B2 (ja) ヒトｒｐｅ細胞医薬品およびその使用
CA2995977C (en) Clinical formulations
EA047097B1 (ru) Клинические композиции
TW202416830A (zh) 細胞冷凍保存調配物及使用方法
NZ740608B2 (en) Clinical formulations
US20210220515A1 (en) Viscoelastic agent material
US20150051558A1 (en) Composition and method for corneal proliferation

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM